搜索
Eton Pharmaceuticals Inc
ETON添加自选
30.260USD
+0.300+1.00%
收盘 05/15, 16:00（美东）报价延迟15分钟
827.91M总市值
亏损市盈率 TTM
查看详细走势图
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+1.00%
5天
+2.06%
1月
+23.86%
6月
+78.63%
今年开始到现在
+78.95%
1年
+59.85%
TradingKey Eton Pharmaceuticals Inc股票评分
单位: USD 更新时间: 2026-05-15操作建议
Eton Pharmaceuticals Inc当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在药品行业排名40/155位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价39.33。中期看，股价处于上升通道。近一个月，市场表现很强，技术面和基本面综合得分较高，很强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Eton Pharmaceuticals Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Eton Pharmaceuticals Inc亮点
亮点风险
Eton Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company has six commercial rare disease products: INCRELEX, ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. INCRELEX is a biologic product used to treat pediatric patients 2 years of age and older who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD). ALKINDI SPRINKLE is for the treatment of pediatric adrenocortical insufficiency. Carglumic Acid is for the treatment of hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is for the treatment of homocystinuria. Nitisinone is for the treatment of hereditary tyrosinemia type 1 (HT-1). PKU GOLIKE is a medical formula for patients with phenylketonuria (PKU). Galzin, its product, is FDA-approved for the treatment of the ultra-rare metabolic condition of Wilson Disease.
业绩高增长
公司营业收入稳步增长，连续3年增长152.67%
业绩增长期
公司处于发展阶段，最新年度总收入79.95M美元
利润高增长
公司净利润处于行业前列，最新年度总收入79.95M美元
估值低估
公司最新PE估值-544.54，处于3年历史低位
机构减仓
最新机构持股15.99M股，环比减少18.71%
PRFDX持仓
明星投资者PRFDX持仓，最新持仓市值2.80K
分析师目标
根据
3
位分析师
买入
评级
39.333
目标均价
+27.62%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Eton Pharmaceuticals Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Eton Pharmaceuticals Inc简介
Eton Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company has six commercial rare disease products: INCRELEX, ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. INCRELEX is a biologic product used to treat pediatric patients 2 years of age and older who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD). ALKINDI SPRINKLE is for the treatment of pediatric adrenocortical insufficiency. Carglumic Acid is for the treatment of hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is for the treatment of homocystinuria. Nitisinone is for the treatment of hereditary tyrosinemia type 1 (HT-1). PKU GOLIKE is a medical formula for patients with phenylketonuria (PKU). Galzin, its product, is FDA-approved for the treatment of the ultra-rare metabolic condition of Wilson Disease.
公司代码ETON
公司Eton Pharmaceuticals Inc
CEOBrynjelsen (Sean E)
网址https://etonpharma.com/
相关品种
